Please assess the completion status of the following clinical trial:

Trial Title: One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet all pre-entry criteria;~* Consent to participate and to be followed for the duration of the study;~* Present the following laboratory values within 14 days prior to inclusion:~  * Hemoglobin \> 8.0 mg/dl~ * Absolute neutrophil count \> 1000 cells/mm3~ * Platelets \> 100,000 cells/mm3~ * Serum creatinine \< 1.5 mg/dl (women with a serum creatinine \> 1.5 mg/dl must have a measured eight-hour urine creatinine clearance \> 70 ml/min)~ * SGPT less than 10 times the upper limit of normal~ * Amylase less than 150/L IU (this upper limit may change slightly depending on the normal range at the hospital laboratory).~Exclusion Criteria:~* Evidence of pre-existing fetal anomalies incompatible with life;~* Known hypersensitivity to any benzodiazepine or to NVP;~* Receipt of antiretroviral agent other than ZDV;~* Receipt of non-allowed concomitant treatment or contraindication to ddI~* Concurrent participation in another clinical trial;~* Women with a CD4 count \<200/µL or history of oral candidiasis if they are not receiving pneumocystis carinii pneumonia (PCP) prophylaxis~* Any other contra-indicated drugs during ZDV+ddI treatment for the mother as well as the child (Contra-indicated drugs such as gancyclovir, isoniazid, linezolid, ethambutol, rifabutin, cidofovir are not allowed during the ZDV ddI treatment after delivery in order to prevent pharmacological interactions or overlapping toxicities.)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).